John D Minna

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6116638/publications.pdf

Version: 2024-02-01

284	38,187	2970	3102
papers	citations	93 h-index	187 g-index

300	300	300	39438
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. Journal of the National Cancer Institute, 2005, 97, 339-346.	3.0	2,194
2	Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA - Journal of the American Medical Association, 2014, 311, 1998.	3.8	1,386
3	Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature, 1985, 316, 823-826.	13.7	1,337
4	Characterizing the cancer genome in lung adenocarcinoma. Nature, 2007, 450, 893-898.	13.7	1,020
5	A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature, 2010, 463, 184-190.	13.7	972
6	Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nature Genetics, 2012, 44, 1111-1116.	9.4	906
7	Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature, 1983, 306, 194-196.	13.7	863
8	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genetics, 2009, 41, 1238-1242.	9.4	862
9	An Epithelialâ€“Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. Clinical Cancer Research, 2013, 19, 279-290.	3.2	848
10	Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery, 2015, 5, 860-877.	7.7	696
11	Epigenetic Inactivation of RASSF1A in Lung and Breast Cancers and Malignant Phenotype Suppression. Journal of the National Cancer Institute, 2001, 93, 691-699.	3.0	695
12	Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature Reviews Cancer, 2019, 19, 289-297.	12.8	692
13	BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene, 1998, 16, 1097-1112.	2.6	636
14	Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery. PLoS ONE, 2009, 4, e6146.	1.1	622
15	L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature, 1985, 318, 69-73.	13.7	607
16	Immortalization of Human Bronchial Epithelial Cells in the Absence of Viral Oncoproteins. Cancer Research, 2004, 64, 9027-9034.	0.4	573
17	Small-cell lung cancer: what we know, what we need to know and the path forward. Nature Reviews Cancer, 2017, 17, 725-737.	12.8	558
18	Differential expression of myc family genes during murine development. Nature, 1986, 319, 780-783.	13.7	520

#	Article	IF	Citations
19	CNS metastases in small cell bronchogenic carcinoma.Increasing frequency and changing pattern with lengthening survival. Cancer, 1979, 44, 1885-1893.	2.0	461
20	Focus on lung cancer. Cancer Cell, 2002, 1, 49-52.	7.7	456
21	A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nature Communications, 2014, 5, 3887.	5.8	456
22	Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature, 2007, 446, 815-819.	13.7	438
23	Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. Cancer Discovery, 2012, 2, 798-811.	7.7	432
24	Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. Journal of the National Cancer Institute, 2012, 104, 228-239.	3.0	424
25	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell, 2021, 39, 346-360.e7.	7.7	422
26	PIK3CA Mutations and Copy Number Gains in Human Lung Cancers. Cancer Research, 2008, 68, 6913-6921.	0.4	399
27	Nrf2 and Keap1 Abnormalities in Nonâ€“Small Cell Lung Carcinoma and Association with Clinicopathologic Features. Clinical Cancer Research, 2010, 16, 3743-3753.	3.2	380
28	Aldehyde Dehydrogenase Activity Selects for Lung Adenocarcinoma Stem Cells Dependent on Notch Signaling. Cancer Research, 2010, 70, 9937-9948.	0.4	357
29	Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 2001, 20, 1509-1518.	2.6	341
30	ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. Cell Reports, 2016, 16, 1259-1272.	2.9	340
31	Promoter Methylation and Silencing of the Retinoic Acid Receptor-Â Gene in Lung Carcinomas. Journal of the National Cancer Institute, 2000, 92, 1303-1307.	3.0	334
32	Mechanical regulation of glycolysis via cytoskeleton architecture. Nature, 2020, 578, 621-626.	13.7	327
33	Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene, 1999, 18, 643-650.	2.6	315
34	Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis. Cancer Research, 2005, 65, 5561-5570.	0.4	309
35	Molecular Genetics of Lung Cancer. Annual Review of Medicine, 2003, 54, 73-87.	5.0	289
36	Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Research, 2005, 65, 226-35.	0.4	283

#	Article	IF	Citations
37	Mutations and addiction to EGFR: the Achilles â€˜healâ€™ of lung cancers?. Trends in Molecular Medicine, 2004, 10, 481-486.	3.5	273
38	Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. International Journal of Cancer, 1998, 78, 766-774.	2.3	270
39	ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. Journal of Clinical Investigation, 2016, 126, 3219-3235.	3.9	256
40	Multiple Oncogenic Changes (K-RASV12, p53 Knockdown, Mutant EGFRs, p16 Bypass, Telomerase) Are Not Sufficient to Confer a Full Malignant Phenotype on Human Bronchial Epithelial Cells. Cancer Research, 2006, 66, 2116-2128.	0.4	247
41	NCI-navy medical oncology branch cell line data base. Journal of Cellular Biochemistry, 1996, 63, 32-91.	1.2	244
42	Chromosome 19 Translocation, Overexpression of Notch3, and Human Lung Cancer. Journal of the National Cancer Institute, 2000, 92, 1355-1357.	3.0	240
43	A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies. PLoS Medicine, 2006, 3, e486.	3.9	228
44	A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Nonâ€“Small Cell Lung Cancer Patients. Clinical Cancer Research, 2013, 19, 1577-1586.	3.2	226
45	CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature, 2017, 546, 168-172.	13.7	222
46	miR-93, miR-98, and miR-197 Regulate Expression of Tumor Suppressor Gene FUS1. Molecular Cancer Research, 2009, 7, 1234-1243.	1.5	209
47	ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14788-14793.	3.3	205
48	Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. Cell Reports, 2016, 16, 1614-1628.	2.9	205
49	LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma. Cancer Research, 2019, 79, 3251-3267.	0.4	196
50	Molecular Biology of Lung Cancer: Clinical Implications. Clinics in Chest Medicine, 2011, 32, 703-740.	0.8	194
51	Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations. Molecular Cancer Research, 2013, 11, 638-650.	1.5	192
52	Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research. Journal of the National Cancer Institute, 2010, 102, 1310-1321.	3.0	182
53	Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene, 1998, 17, 1557-1565.	2.6	181
54	New molecularly targeted therapies for lung cancer. Journal of Clinical Investigation, 2007, 117, 2740-2750.	3.9	180

#	Article	IF	Citations
55	Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?. Clinical Cancer Research, 2015, 21, 2244-2255.	3.2	179
56	Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines. PLoS ONE, 2009, 4, e4576.	1.1	177
57	Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Translational Lung Cancer Research, 2018, 7, 32-49.	1.3	173
58	Molecular biology of lung cancer. Journal of Thoracic Disease, 2013, 5 Suppl 5, S479-90.	0.6	173
59	The clinical behavior of â€žmixedâ€•small cell/large cell bronchogenic carcinoma compared to â€žpureâ€• small cell subtypes. Cancer, 1982, 50, 2894-2902.	2.0	169
60	Molecular Pathogenesis of Lung Cancer. Annual Review of Physiology, 2002, 64, 681-708.	5.6	169
61	Different Roles for Caveolin-1 in the Development of Non-Small Cell Lung Cancer versus Small Cell Lung Cancer. Cancer Research, 2004, 64, 4277-4285.	0.4	168
62	Functional Properties of a New Voltage-dependent Calcium Channel Î±2Î´ Auxiliary Subunit Gene (CACNA2D2). Journal of Biological Chemistry, 2000, 275, 12237-12242.	1.6	165
63	CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Research, 2017, 77, 3870-3884.	0.4	163
64	XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature, 2016, 538, 114-117.	13.7	162
65	Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. , 1998, 21, 308-319.		158
66	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of Thoracic Oncology, 2016, 11, 453-474.	0.5	156
67	Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer and Metastasis Reviews, 2010, 29, 61-72.	2.7	154
68	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutationsâ€"The Lung Cancer Mutation Consortium (LCMC2). Clinical Cancer Research, 2018, 24, 1038-1047.	3.2	154
69	Nsp1 protein of SARS-CoV-2 disrupts the mRNA export machinery to inhibit host gene expression. Science Advances, 2021, 7, .	4.7	154
70	Artificial Intelligence in Lung Cancer Pathology Image Analysis. Cancers, 2019, 11, 1673.	1.7	152
71	Knockdown of Oncogenic KRAS in Nonâ€“Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy. Molecular Cancer Therapeutics, 2011, 10, 336-346.	1.9	151
72	Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer. Cell, 2013, 155, 552-566.	13.5	151

#	Article	IF	Citations
73	Progress in understanding the molecular pathogenesis of human lung cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 1998, 1378, F21-F59.	3.3	147
74	An Expression Signature as an Aid to the Histologic Classification of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 4880-4889.	3.2	140
75	Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene, 1998, 16, 3151-3157.	2.6	136
76	Aberrant DNA Methylation in Lung Cancer: Biological and Clinical Implications. Oncologist, 2002, 7, 451-457.	1.9	136
77	Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. Cell Metabolism, 2018, 28, 369-382.e5.	7.2	136
78	Clinicopathologic Significance of the Mutations of the Epidermal Growth Factor Receptor Gene in Patients with Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 6816-6822.	3.2	135
79	Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer, 2006, 106, 2200-2207.	2.0	132
80	Essential Role of Aldehyde Dehydrogenase 1A3 for the Maintenance of Nonâ€“Small Cell Lung Cancer Stem Cells Is Associated with the STAT3 Pathway. Clinical Cancer Research, 2014, 20, 4154-4166.	3.2	131
81	Polymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung Cancers. PLoS Medicine, 2007, 4, e125.	3.9	130
82	Molecular pathogenesis of lung cancer. Journal of Thoracic and Cardiovascular Surgery, 1999, 118, 1136-1152.	0.4	119
83	Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells. Molecular Cell, 2019, 76, 838-851.e5.	4.5	119
84	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. Journal of Thoracic Oncology, 2020, 15, 520-540.	0.5	119
85	High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. International Journal of Cancer, 2006, 118, 1556-1564.	2.3	117
86	Sex Determining Region Y-Box 2 (SOX2) Is a Potential Cell-Lineage Gene Highly Expressed in the Pathogenesis of Squamous Cell Carcinomas of the Lung. PLoS ONE, 2010, 5, e9112.	1.1	117
87	The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nature Communications, 2017, 8, 15503.	5.8	116
88	Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget, 2016, 7, 3548-3558.	0.8	114
89	Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14112-14117.	3.3	113
90	Pten Inactivation Accelerates Oncogenic K-rasâ€“Initiated Tumorigenesis in a Mouse Model of Lung Cancer. Cancer Research, 2008, 68, 1119-1127.	0.4	111

#	Article	IF	Citations
91	Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?. Lung Cancer, 2010, 68, 309-318.	0.9	109
92	Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. Cancer Cell, 2016, 30, 940-952.	7.7	104
93	Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell, 2018, 173, 864-878.e29.	13.5	102
94	Clinical implications of cytogenetic studies in cutaneous t-cell lymphoma (CTCL). Cancer, 1982, 50, 1539-1553.	2.0	100
95	Proportion of Never-Smoker Nonâ€“Small Cell Lung Cancer Patients at Three Diverse Institutions. Journal of the National Cancer Institute, 2017, 109, djw295.	3.0	97
96	Homozygous deletions at 3p12 in breast and lung cancer. Oncogene, 1998, 17, 1723-1729.	2.6	95
97	Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clinical Cancer Research, 2002, 8, 2362-8.	3.2	95
98	A three-dimensional model of differentiation of immortalized human bronchial epithelial cells. Differentiation, 2006, 74, 141-148.	1.0	89
99	Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Nonâ€“Small Cell Lung Cancer Cells. Journal of the National Cancer Institute, 2014, 106, .	3.0	88
100	Computational Staining of Pathology Images to Study the Tumor Microenvironment in Lung Cancer. Cancer Research, 2020, 80, 2056-2066.	0.4	88
101	SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. Cell Reports, 2020, 33, 108296.	2.9	86
102	CANCER: A Bull's Eye for Targeted Lung Cancer Therapy. Science, 2004, 304, 1458-1461.	6.0	84
103	NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6524-6529.	3.3	84
104	Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene, 2001, 20, 6258-6262.	2.6	82
105	Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. Cell Reports, 2017, 19, 1669-1684.	2.9	82
106	The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer. Nature Metabolism, 2020, 2, 1401-1412.	5.1	82
107	Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer. Genes Chromosomes and Cancer, 2005, 44, 405-414.	1.5	81
108	Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer. Journal of Clinical Investigation, 2003, 111, 31-33.	3.9	81

#	Article	IF	Citations
109	Fine Mapping of Chromosome 6q23-25 Region in Familial Lung Cancer Families Reveals RGS17 as a Likely Candidate Gene. Clinical Cancer Research, 2009, 15, 2666-2674.	3.2	80
110	SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nature Communications, 2017, 8, 14098.	5.8	80
111	Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Nature, 2021, 590, 504-508.	13.7	79
112	LCE: an open web portal to explore gene expression and clinical associations in lung cancer. Oncogene, 2019, 38, 2551-2564.	2.6	78
113	The skin in disseminated intravascular coagulation.. British Journal of Dermatology, 1973, 88, 221-229.	1.4	77
114	Loss and Reduction of Fus1 Protein Expression is a Frequent Phenomenon in the Pathogenesis of Lung Cancer. Clinical Cancer Research, 2008, 14, 41-47.	3.2	74
115	eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. Nature Cancer, 2020, 1, 533-545.	5.7	73
116	TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. Journal of Clinical Investigation, 2018, 128, 2500-2518.	3.9	73
117	Semaphorin 3B Inhibits the Phosphatidylinositol 3-Kinase/Akt Pathway through Neuropilin-1 in Lung and Breast Cancer Cells. Cancer Research, 2008, 68, 8295-8303.	0.4	71
118	TheDUTT1Gene, a Novel NCAM Family Member Is Expressed in Developing Murine Neural Tissues and Has an Unusually Broad Pattern of Expression. Molecular and Cellular Neurosciences, 1998, 11, 29-35.	1.0	68
119	p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. Cell Reports, 2019, 28, 1860-1878.e9.	2.9	68
120	Enrichment of epithelial cells for molecular studies. Nature Medicine, 1999, 5, 459-462.	15.2	67
121	ConvPath: A software tool for lung adenocarcinoma digital pathological image analysis aided by a convolutional neural network. EBioMedicine, 2019, 50, 103-110.	2.7	66
122	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. Journal of Thoracic Oncology, 2020, 15, 973-999.	0.5	66
123	Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathology and Oncology Research, 2001, 7, 6-13.	0.9	65
124	Nuclear Receptor Expression Defines a Set of Prognostic Biomarkers for Lung Cancer. PLoS Medicine, 2010, 7, e1000378.	3.9	65
125	Aiolos Promotes Anchorage Independence by Silencing p66Shc Transcription in Cancer Cells. Cancer Cell, 2014, 25, 575-589.	7.7	64
126	Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respiratory Medicine,the, 2018, 6, 472-478.	5.2	64

#	Article	IF	Citations
127	Molecular genetics of small cell lung carcinoma. Seminars in Oncology, 2001, 28, 3-13.	0.8	63
128	The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis. Cancers, 2021, 13, 6206.	1.7	63
129	Multipotent Capacity of Immortalized Human Bronchial Epithelial Cells. PLoS ONE, 2011, 6, e22023.	1.1	60
130	Expression of c-myc in Progenitor Cells of the Bronchopulmonary Epithelium and in a Large Number of Non-Small Cell Lung Cancers. American Journal of Respiratory Cell and Molecular Biology, 1993, 9, 33-43.	1.4	58
131	Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence. Journal of Thoracic Oncology, 2010, 5, 1894-1904.	0.5	57
132	<scp>TIMELESS</scp> is overexpressed in lung cancer and its expression correlates with poor patient survival. Cancer Science, 2013, 104, 171-177.	1.7	57
133	Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis. Cancer Research, 2019, 79, 125-132.	0.4	56
134	PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis. Cancer Research, 2017, 77, 187-197.	0.4	55
135	Phosphatidylserine receptors enhance SARS-CoV-2 infection. PLoS Pathogens, 2021, 17, e1009743.	2.1	55
136	Synergistic Tumor Suppression by Coexpression of FUS1 and p53 Is Associated with Down-regulation of Murine Double Minute-2 and Activation of the Apoptotic Protease-Activating Factor 1â€“Dependent Apoptotic Pathway in Human Nonâ€“Small Cell Lung Cancer Cells. Cancer Research, 2007, 67, 709-717.	0.4	54
137	A Susceptibility Locus on Chromosome 6q Greatly Increases Lung Cancer Risk among Light and Never Smokers. Cancer Research, 2010, 70, 2359-2367.	0.4	52
138	EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. Nature Cancer, 2020, 1, 394-409.	5.7	51
139	The role of radiation therapy in the treatment of small cell lung cancer. Cancer, 1985, 55, 2163-2175.	2.0	50
140	A big step in the study of small cell lung cancer. Cancer Cell, 2003, 4, 163-166.	7.7	50
141	HORMAD1 Is a Negative Prognostic Indicator in Lung Adenocarcinoma and Specifies Resistance to Oxidative and Genotoxic Stress. Cancer Research, 2018, 78, 6196-6208.	0.4	50
142	Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15q24-25.1. Cancer Research, 2009, 69, 7844-7850.	0.4	49
143	IGFBP2/FAK Pathway Is Causally Associated with Dasatinib Resistance in Nonâ€“Small Cell Lung Cancer Cells. Molecular Cancer Therapeutics, 2013, 12, 2864-2873.	1.9	49
144	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. Clinical Cancer Research, 2015, 21, 3480-3491.	3.2	48

#	Article	IF	Citations
145	NCI series of cell lines: An historical perspective. Journal of Cellular Biochemistry, 1996, 63, 1-11.	1.2	45
146	Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer. Journal of Proteome Research, 2016, 15, 477-486.	1.8	45
147	From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers. Journal of Thoracic Oncology, 2016, 11, 287-299.	0.5	45
148	Identification and Characterization of a Suite of Tumor Targeting Peptides for Non-Small Cell Lung Cancer. Scientific Reports, 2014, 4, 4480.	1.6	44
149	Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer. Communications Biology, 2021, 4, 314.	2.0	44
150	A Systematic Analysis Reveals Heterogeneous Changes in the Endocytic Activities of Cancer Cells. Cancer Research, 2015, 75, 4640-4650.	0.4	43
151	Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis. Cancer Research, 2021, 81, 1813-1826.	0.4	41
152	Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide methods of documenting tumor response and progression. Cancer, 1980, 45, 1300-1310.	2.0	40
153	A Search for Novel Cancer/Testis Antigens in Lung Cancer Identifies VCX/Y Genes, Expanding the Repertoire of Potential Immunotherapeutic Targets. Cancer Research, 2014, 74, 4694-4705.	0.4	40
154	Telomerase-Mediated Strategy for Overcoming Nonâ€“Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. Neoplasia, 2018, 20, 826-837.	2.3	40
155	Genetic Mutation of p53 and Suppression of the miR-17â^¼92 Cluster Are Synthetic Lethal in Nonâ€“Small Cell Lung Cancer due to Upregulation of Vitamin D Signaling. Cancer Research, 2015, 75, 666-675.	0.4	39
156	Dual targeting of CTLA-4 and CD47 on T _{reg} cells promotes immunity against solid tumors. Science Translational Medicine, 2021, 13, .	5.8	39
157	RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. Cell Chemical Biology, 2020, 27, 105-121.e14.	2.5	38
158	Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner. Oncotarget, 2016, 7, 31639-31651.	0.8	38
159	Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Nonâ€“Small Cell Lung Cancers. Cancer Research, 2017, 77, 3070-3081.	0.4	36
160	Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1. Oncotarget, 2016, 7, 30678-30690.	0.8	36
161	Systematic siRNA Screen Unmasks NSCLC Growth Dependence by Palmitoyltransferase DHHC5. Molecular Cancer Research, 2015, 13, 784-794.	1.5	35
162	Transmembrane Protease TMPRSS11B Promotes Lung Cancer Growth by Enhancing Lactate Export and Glycolytic Metabolism. Cell Reports, 2018, 25, 2223-2233.e6.	2.9	34

#	Article	IF	Citations
163	Altered Regulation of HIF-1Î± in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. Journal of Thoracic Oncology, 2021, 16, 439-451.	0.5	34
164	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2â€“Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. Journal of Thoracic Oncology, 2021, 16, 1821-1839.	0.5	34
165	Cancer-Specific Production of N-Acetylaspartate via NAT8L Overexpression in Nonâ€“Small Cell Lung Cancer and Its Potential as a Circulating Biomarker. Cancer Prevention Research, 2016, 9, 43-52.	0.7	33
166	Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer. Journal of Clinical Investigation, 2021, 131, .	3.9	33
167	High-throughput functional evaluation of human cancer-associated mutations using base editors. Nature Biotechnology, 2022, 40, 874-884.	9.4	32
168	Loss of heterozygosity of chromosome 12p does not correlate withKRAS mutation in non-small cell lung cancer. International Journal of Cancer, 2003, 107, 962-969.	2.3	31
169	Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: Comparison of non-small cell lung cancer and small cell lung cancer. Journal of Cellular Biochemistry, 1996, 63, 173-185.	1.2	30
170	Branching morphogenesis of immortalized human bronchial epithelial cells in three-dimensional culture. Differentiation, 2014, 87, 119-126.	1.0	30
171	Two regions of homozygous deletion clusters at chromosome band 9p21 in human lung cancer. Genes Chromosomes and Cancer, 2000, 27, 308-318.	1.5	29
172	Predicting the future for people with lung cancer. Nature Medicine, 2008, 14, 812-813.	15.2	29
173	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 TÂcells. Cell Reports Medicine, 2022, 3, 100554.	3.3	29
174	Radiation-Enhanced Lung Cancer Progression in a Transgenic Mouse Model of Lung Cancer Is Predictive of Outcomes in Human Lung and Breast Cancer. Clinical Cancer Research, 2014, 20, 1610-1622.	3.2	28
175	Unbiased Selection of Peptideâ€“Peptoid Hybrids Specific for Lung Cancer Compared to Normal Lung Epithelial Cells. ACS Chemical Biology, 2015, 10, 2891-2899.	1.6	28
176	Monitoring drug induced apoptosis and treatment sensitivity in non-small cell lung carcinoma using dielectrophoresis. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 1877-1883.	1.1	28
177	Refined mapping of two regions of loss of heterozygosity on chromosome band 11q23 in lung cancer. , 1999, 25, 154-159.		27
178	Estrogen Receptor Beta-Mediated Modulation of Lung Cancer Cell Proliferation by 27-Hydroxycholesterol. Frontiers in Endocrinology, 2018, 9, 470.	1.5	27
179	Unbiased peptoid combinatorial cell screen identifies plectin protein as a potential biomarker for lung cancer stem cells. Scientific Reports, 2019, 9, 14954.	1.6	27
180	Developing EZH2-Targeted Therapy for Lung Cancer. Cancer Discovery, 2016, 6, 949-952.	7.7	26

#	Article	IF	Citations
181	Subtype-specific secretomic characterization of pulmonary neuroendocrine tumor cells. Nature Communications, 2019, 10, 3201.	5.8	26
182	Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. Journal of Thoracic Oncology, 2022, 17, 214-227.	0.5	26
183	Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas. Lung Cancer, 2014, 85, 282-292.	0.9	25
184	Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines. Oncogene, 1997, 14, 1231-1234.	2.6	24
185	The human homolog of the rodent immediate early response genes, PC4 and TIS7, resides in the lung cancer tumor suppressor gene region on chromosome 3p21. Human Genetics, 1997, 99, 334-341.	1.8	24
186	Precise localization of theFHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletions within FRA3B that affectFHIT transcription in tumor cell lines. , 1997, 20, 16-23.		24
187	Pivotal role of epithelial cell adhesion molecule in the survival of lung cancer cells. Cancer Science, 2011, 102, 1493-1500.	1.7	24
188	Two identical triplet sisters carrying a germlineBRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome. Genes Chromosomes and Cancer, 2000, 28, 359-369.	1.5	22
189	Tumor Oncogenotypes and Lung Cancer Stem Cell Identity. Cell Stem Cell, 2010, 7, 2-4.	5.2	22
190	Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget, 2017, 8, 11114-11126.	0.8	22
191	Co-immunoprecipitation and semi-quantitative immunoblotting for the analysis of protein-protein interactions. STAR Protocols, 2021, 2, 100644.	0.5	22
192	An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis. Neoplasia, 2020, 22, 294-310.	2.3	21
193	ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung cancer. IScience, 2021, 24, 102953.	1.9	21
194	<scp>eIF</scp>2Î², a subunit of translationâ€initiation factor <scp>EIF</scp>2, is a potential therapeutic target for nonâ€small cell lung cancer. Cancer Science, 2018, 109, 1843-1852.	1.7	20
195	LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer. Oncotarget, 2018, 9, 29601-29618.	0.8	19
196	Identification of proteasomal catalytic subunit <scp>PSMA</scp>6 as a therapeutic target for lung cancer. Cancer Science, 2017, 108, 732-743.	1.7	18
197	Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers. Oncogene, 2001, 20, 1005-1009.	2.6	17
198	A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 31-37.	0.5	16

#	Article	IF	Citations
199	A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 31-37.	0.5	16
200	EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. Nature Clinical Practice Oncology, 2006, 3, 170-171.	4.3	16
201	Abdominal computed tomography in small cell lung cancer: Assessment of extent of disease and response to therapy. Cancer, 1982, 49, 1485-1490.	2.0	15
202	Adaptive Prediction Model in Prospective Molecular Signatureâ€"Based Clinical Studies. Clinical Cancer Research, 2014, 20, 531-539.	3.2	15
203	Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer. Journal of the American Society for Mass Spectrometry, 2017, 28, 2078-2089.	1.2	15
204	Immortalized normal human lung epithelial cell models for studying lung cancer biology. Respiratory Investigation, 2020, 58, 344-354.	0.9	15
205	Snail acetylation by autophagyâ€derived acetylâ€coenzyme A promotes invasion and metastasis of KRASâ€LKB1 coâ€mutated lung cancer cells. Cancer Communications, 2022, 42, 716-749.	3.7	15
206	The hematopoietic toxicity of regional radiation therapy. Correlations for combined modality therapy with systemic chemotherapy. Cancer, 1985, 55, 1429-1435.	2.0	14
207	The Epithelial Sodium Channel (Î±ENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors. Translational Oncology, 2018, 11, 292-299.	1.7	14
208	Transcription factors and recessive oncogenes in the pathogenesis of human lung cancer. International Journal of Cancer, 1989, 44, 32-34.	2.3	13
209	NeuroD1 mediates nicotine-induced migration and invasion via regulation of the nicotinic acetylcholine receptor subunits in a subset of neural and neuroendocrine carcinomas. Molecular Biology of the Cell, 2014, 25, 1782-1792.	0.9	13
210	Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Research, 2018, 78, 1986-1999.	0.4	13
211	A quantitative method for assessing smoke associated molecular damage in lung cancers. Translational Lung Cancer Research, 2018, 7, 439-449.	1.3	13
212	Identifying a missing lineage driver in a subset of lung neuroendocrine tumors. Genes and Development, 2018, 32, 865-867.	2.7	13
213	Systematic Analysis of Gene Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma with a Case Study of FAM83A and FAM83B. Cancers, 2019, 11, 886.	1.7	13
214	ClickGene: an open cloud-based platform for big pan-cancer data genome-wide association study, visualization and exploration. BioData Mining, 2019, 12, 12.	2.2	13
215	Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer. Clinical Cancer Research, 2019, 25, 150-157.	3.2	13
216	Ubiquitin Câ€terminal hydrolaseâ€L1 has prognostic relevance and is a therapeutic target for highâ€grade neuroendocrine lung cancers. Cancer Science, 2020, 111, 610-620.	1.7	13

#	Article	IF	Citations
217	On comparing heterogeneity across biomarkers. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 558-567.	1.1	12
218	Nuclear Receptor Expression and Function in Human Lung Cancer Pathogenesis. PLoS ONE, 2015, 10, e0134842.	1.1	12
219	Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines. PLoS ONE, 2016, 11, e0150963.	1.1	12
220	Ras transformation uncouples the kinesin-coordinated cellular nutrient response. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10568-10573.	3.3	11
221	Elucidation of changes in molecular signalling leading to increased cellular transformation in oncogenically progressed human bronchial epithelial cells exposed to radiations of increasing LET. Mutagenesis, 2015, 30, 685-694.	1.0	11
222	Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer. Bioinformatics, 2016, 32, 1373-1379.	1.8	11
223	Developing New, Rational Therapies for Recalcitrant Small Cell Lung Cancer. Journal of the National Cancer Institute, 2016, 108, djw119.	3.0	11
224	Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair. Radiation Research, 2016, 185, 527-538.	0.7	11
225	Kub5-HeraRPRD1B Deficiency Promotes â€œBRCAnessâ€•and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers. Clinical Cancer Research, 2018, 24, 6459-6470.	3.2	11
226	SLC43A3 Is a Biomarker of Sensitivity to the Telomeric DNA Damage Mediator 6-Thio-2â€²-Deoxyguanosine. Cancer Research, 2020, 80, 929-936.	0.4	10
227	A Call to Action: Dismantling Racial Injustices in Preclinical Research and Clinical Care of Black Patients Living with Small Cell Lung Cancer. Cancer Discovery, 2021, 11, 240-244.	7.7	10
228	Identification of a Human Airway Epithelial Cell Subpopulation with Altered Biophysical, Molecular, and Metastatic Properties. Cancer Prevention Research, 2017, 10, 514-524.	0.7	9
229	Expression of feline xenotropic RNA tumor virus in hybrids between permissive human and non-permissive mouse cells. International Journal of Cancer, 1979, 24, 826-834.	2.3	8
230	Development and Validation of a Pathology Image Analysis-based Predictive Model for Lung Adenocarcinoma Prognosis - A Multi-cohort Study. Scientific Reports, 2019, 9, 6886.	1.6	8
231	A Proteomic Connectivity Map for Characterizing the Tumor Adaptive Response to Small Molecule Chemical Perturbagens. ACS Chemical Biology, 2020, 15, 140-150.	1.6	8
232	Evaluation of response to chemotherapy with fiberoptic bronchoscopy in non-small cell lung cancer. Cancer, 1980, 45, 1693-1696.	2.0	7
233	MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Nonâ€“Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0150467.	1.1	7
234	Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?. Journal of Thoracic Oncology, 2019, 14, 332-335.	0.5	7

#	Article	IF	Citations
235	Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers, 2021, 13, 1250.	1.7	7
236	SH3BP4 promotes neuropilin-1 and Î±5-integrin endocytosis and is inhibited by Akt. Developmental Cell, 2021, 56, 1164-1181.e12.	3.1	7
237	ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience.. Journal of Clinical Oncology, 2012, 30, 7589-7589.	0.8	7
238	Exosome mediated phenotypic changes in lung cancer pathophysiology. Translational Cancer Research, 2017, 6, S1040-S1042.	0.4	7
239	FRA1 contributes to MEK-ERK pathway-dependent PD-L1 upregulation by KRAS mutation in premalignant human bronchial epithelial cells. American Journal of Translational Research (discontinued), 2020, 12, 409-427.	0.0	7
240	Small cell lung cancers made from scratch. Journal of Experimental Medicine, 2019, 216, 476-478.	4.2	6
241	Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis. PLoS ONE, 2019, 14, e0208646.	1.1	6
242	From clinical specimens to human cancer preclinical modelsâ€"a journey the NCIâ€cell line databaseâ€"25 years later. Journal of Cellular Biochemistry, 2020, 121, 3986-3999.	1.2	6
243	Studying Lineage Plasticity One Cell at a Time. Cancer Cell, 2020, 38, 150-152.	7.7	6
244	Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations. Cancer Research, 2021, 81, 4685-4695.	0.4	6
245	Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. Journal of Thoracic Oncology, 2021, 16, 2051-2064.	0.5	6
246	Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. Nature Communications, 2021, 12, 7014.	5.8	6
247	Unbiased peptoid cell screen identifies a peptoid targeting newly appeared cell surface vimentin on tumor transformed early lung cancer cells. Bioorganic and Medicinal Chemistry, 2022, 58, 116673.	1.4	6
248	Comparison between concurrent and sequential chemoradiation for non-small cell lung cancer in vitro. Oncology Letters, 2014, 7, 307-310.	0.8	5
249	KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. American Journal of Cancer Research, 2020, 10, 4464-4475.	1.4	5
250	High-dose methotrexate with leucovorin rescue in patients with unresectable non-small cell carcinoma of the lung. Cancer, 1983, 52, 1778-1782.	2.0	4
251	Karyotypic Derivation of H9 Cell Line. Journal of the National Cancer Institute, 1993, 85, 1168-1168.	3.0	4
252	Assessing consistency across functional screening datasets in cancer cells. Bioinformatics, 2021, 37, 4540-4547.	1.8	4

#	Article	IF	Citations
253	Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. Molecular Cancer Research, 2022, 20, 280-292.	1.5	4
254	AP-1 leads the way in lung cancer transformation. Developmental Cell, 2022, 57, 292-294.	3.1	4
255	Latent feature decompositions for integrative analysis of diverse high-throughput genomic data. , 2012, , .		3
256	Opening a Chromatin Gate to Metastasis. Cell, 2016, 166, 275-276.	13.5	3
257	Molecular differences across invasive lung adenocarcinoma morphological subgroups. Translational Lung Cancer Research, 2020, 9, 1029-1040.	1.3	3
258	A rational targeted therapy for platinum-resistant small-cell lung cancer. Cancer Cell, 2021, 39, 453-456.	7.7	3
259	How lung cancer cells change identity. ELife, 2021, 10, .	2.8	3
260	Use of proteomic analysis of LKB1/AMPK/mTOR pathways to identify IGF-1R pathway upregulation with LKB1 loss or mTOR inhibition in NSCLC: Implications for targeted combinations.. Journal of Clinical Oncology, 2012, 30, 10612-10612.	0.8	3
261	Selecting Reliable mRNA Expression Measurements across Platforms Improves Downstream Analysis. Cancer Informatics, 2016, 15, CIN.S38590.	0.9	2
262	Evaluating tumor-suppressor gene combinations. Nature Genetics, 2018, 50, 480-482.	9.4	2
263	Different Originating Cells Underlie Intertumoral Heterogeneity in Lung Neuroendocrine Tumors. Cancer Discovery, 2018, 8, 1216-1218.	7.7	2
264	Effects of entinostat onresistance to cetuximab and EGFR TKIs in non-small cell lung cancer.. Journal of Clinical Oncology, 2012, 30, e18077-e18077.	0.8	2
265	Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy. Cancer Cell, 2021, 39, 1455-1457.	7.7	2
266	Longitudinal COVID-19 Vaccinationâ€“Induced Antibody Responses and Omicron Neutralization in Patients With Lung Cancer. Journal of Clinical Oncology, 0, , .	0.8	2
267	Molecular Basis of Lung Cancer. , 2015, , 475-490.e1.		1
268	Defining the First Part of the Oncogenic KRAS Journey. Cell Stem Cell, 2020, 27, 499-500.	5.2	1
269	Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3351-3368.	1.3	1
270	Contemporary Lung Cancer Screening and the Promise of Blood-Based Biomarkers. Cancer Research, 2021, 81, 3441-3443.	0.4	1

#	Article	IF	Citations
271	Immortalization of human small airway epithelial cells with characteristics of bronchioalveolar stem cells. FASEB Journal, 2009, 23, LB340.	0.2	1
272	Investigation of PARP1 as a therapeutic target in small cell lung cancer.. Journal of Clinical Oncology, 2012, 30, 7096-7096.	0.8	1
273	Lung Cancer Computational Biology and Resources. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a038273.	2.9	1
274	Establishment of reference standards for multifaceted mosaic variant analysis. Scientific Data, 2022, 9, 35.	2.4	1
275	Resistance to mutant KRAS-induced senescence in an hTERT/Cdk4-immortalized normal human bronchial epithelial cell line. Experimental Cell Research, 2022, 414, 113053.	1.2	1
276	AIF: an acquired metabolic liability in lung cancer. Cell Research, 2019, 29, 607-608.	5.7	0
277	Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?. EBioMedicine, 2020, 60, 103006.	2.7	0
278	Abstract PO021: Lung cancer cells and cancer-associated fibroblasts drive macrophage polarization in a co-culture model. , 2021, , .		0
279	Abstract S01-02: Assessing vulnerability of patients with lung cancer to SARS-CoV-2 infection based on serological antibody analyses. , 2021, , .		0
280	An innovative role of thyroid receptor Î² in tripleâ€negative breast cancer (58.4). FASEB Journal, 2014, 28, 58.4.	0.2	0
281	Abstract A22: Differential MYC dependence in NSCLC identified through pharmacological and genetic MYC inhibition. , 2015, , .		0
282	602â€…AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells. , 2021, 9, A632-A632.		0
283	Elucidating Mechanisms of Acquired Resistance to IDH Inhibition By Saturation Variant Screening of Base-Edited Leukemia Cells. Blood, 2020, 136, 3-3.	0.6	0
284	Lung Cancer Cell of Origin: Controversy and Clinical Translational Implications. Cancer Research, 2022, 82, 972-973.	0.4	0